UHS Stock Analysis
NYQ · Healthcare · Medical Care Facilities
$180.88
+2.02 (+1.13%)
UHS Interactive Price Chart & Trading Signals
UHS Stock Snapshot — Valuation, Risk & Technical Signals
UHS Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$10.66B
P/E Ratio
7.38
Forward P/E
7.54
PEG Ratio
1.21
P/B Ratio
1.42
EPS
$24.50
Dividend Yield
0.45%
52W Range
$140.08 – $246.33
Beta
1.06
Volume
0.1M
ROE
20.9%
Profit Margin
8.4%
Revenue Growth
8.3%
Gross Margin
44.6%
EV/EBITDA
5.86
Analyst Target
$194.35
The trailing price-to-earnings ratio stands at 7.4x. Forward P/E of 7.5x indicates stable forward expectations. Price-to-book is 1.42x. EV/EBITDA sits at 5.86x. Market capitalization is $10.66B. Revenue is growing at 8.3% on a trailing basis. Earnings are expanding at 10.1%. Profit margins are 8.4%. Return on equity is 20.9%. Beta of 1.06 indicates market-average volatility.
Analyst Consensus
Recommendation
Buy
Low Target
$166.00
Mean Target
$194.35
High Target
$290.00
Based on 17 analysts
About UHS
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities in the United States. It operates through Acute Care Hospital Services and Behavioral Health Care Services segments. The company's hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric, pharmacy, and/or behavioral health services. It also provides commercial health insurance services; capital resources; and various management services, including central purchasing, information services, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
UHS Deep Dive Analysis
Bottom Line
Verdict
UndervaluedBest for
Value-oriented investorsWatch out for
None flaggedNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
Universal Health Services, Inc. (UHS) trades below our multi-model fair value estimate of $363.91 by approximately 101.2%. Trailing P/E: 7.4x. Profitability signals include profit margin of 8.4% and return on equity of 20.9%. Recent growth metrics show revenue growth of 8.3% and earnings growth of 10.1%. Risk profile: beta of 1.06. Consensus: buy.
Valuation, Growth & Risk
Valuation
Undervalued
P/E 7.4x
Price sits below our estimate of fair value.
Growth
Expanding
Rev 8.3%
Revenue is outpacing the market.
Valuation Snapshot
Universal Health Services, Inc. (UHS) trades below our multi-model fair value estimate of $363.91 by approximately 101.2%. The trailing price-to-earnings ratio stands at 7.4x. Forward P/E of 7.5x indicates stable forward expectations. Price-to-sales is 0.6x. Price-to-book is 1.4x. EV/EBITDA sits at 5.9x. Market capitalization is $10.66B.
Why it matters: Buying below fair value can create a margin of safety, but always check earnings quality.
Growth & Profitability
Revenue is growing at 8.3% on a trailing basis. Earnings are expanding at 10.1%. Profit margins are 8.4%. Return on equity is 20.9%. Return on assets is 8.3%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 1.06 indicates market-average volatility. Net debt position is $5.12B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $194.35 implies 7.4% upside. Target range spans $166.00 to $290.00. 17 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Investor Fit
The combination of undervaluation and moderate risk may suit value-oriented investors. Free cash flow yield of 7.7% is attractive for cash-flow-focused investors.
Takeaway: Match the stock's risk-reward profile with your own goals and time horizon. No single metric tells the whole story.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
UHS Undervalued
Universal Health Services, Inc. (UHS) trades below our multi-model fair value estimate of $363.91 by approximately 101.2%.
Frequently Asked Questions
ValuationIs UHS stock overvalued right now?
ValuationWhat is UHS fair value based on current fundamentals?
RiskHow risky is UHS compared with other stocks?
GrowthIs UHS still growing?
AnalystWhat do analysts think about UHS?
DividendDoes UHS pay a dividend?
CatalystWhat could change the investment case for UHS?
Related Stocks
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.